**DHD: Annual General Mandate 2024**

On April 2, 2024, Hai Duong Pharmaceutical Medical Materials Joint Stock Company announced General Mandate No. 02/2024/NQ-DHDCD-DHD as follows:

‎‎Article 1. Approve the profit distribution plan in 2023 and financial estimate in 2024 according to Proposal No. 01/Ttr-HDQT of the Board of Directors.

Profit distribution plan for fiscal year 2023 and profit transferred from the previous year.

|  |  |  |
| --- | --- | --- |
| No. | Target | Amount (VND) |
| 1 | Undistributed profit transferred from the previous year | 10,268,002,632 |
| 2 | Total profit after tax in 2023 | 31,514,069,929 |
| 3 | Dividend payment in 2023 at the rate of 3%  Methods:   * Pay in cash at the rate of 3%: VND 6,119,889,000 | 6,119,889,000 |
| 4 | Remuneration of members of the Board of Directors and the Supervisory Board not participating in management in 2023 settled according to the Charter | 315,140,700 |
| 5 | Total remaining undistributed profit  (5=1+2-3-4) | 35,347,042,861 |
| 6 | Total undistributed profits transferred to the next year | 35,347,042,861 |

‎‎Article 2. Approve remuneration of the Board of Directors and the Supervisory Board in 2023 and proposal in 2024 according to Proposal No. 02/Ttr-HDQT of the Board of Directors.

‎‎Article 3. Approve selecting an audit company for the Financial Statements 2024 according to Proposal No. 03/Ttr-HDQT of the Board of Directors.

‎‎Article 4. Approve the Audited Financial Statements 2023 according to Proposal No. 04/Ttr-HDQT of the Board of Directors.

‎‎Article 5. Approve the Reports submitted to the Meeting according to Proposal No. 05/Ttr-HDQT of the Board of Directors, specifically as follows:

* Report on activities of the Board of Directors in 2023;
* Report on the activities of the Supervisory Board in 2023;
* Report on production and business activities in 2023 and plan in 2024.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No. | Target | Unit | Results of plan implementation | | | | |
| 2019 | 2020 | 2021 | 2022 | 2023 |
| 1 | Total revenue | Million VND | 666,959 | 644,658 | 621,791 | 617,510 | 616,251 |
| 2 | Total production value | Million VND | 272,668 | 260,915 | 282,480 | 320,534 | 333,176 |
| 3 | Average income | VND 1,000/person/month | 7,590 | 8,375 | 8,543 | 10,600 | 10,800 |
| 4 | Profit before tax | Million VND | 33,306 | 35,925 | 37,173 | 37,766 | 39,492 |

‎‎Article 6. Approve the share issuance plan to increase capital from the source of owners’ equity in 2024 according to Proposal No. 06/Ttr-HDQT of the Board of Directors.

Share issuance plan to increase share capital from the source of owners’ equity in 2024

|  |  |
| --- | --- |
| 1. Issuer | Hai Duong Pharmaceutical Medical Materials Joint Stock Company |
| 1. Share type | Common share. |
| 1. Number of issued shares | 7,547,863 shares. |
| 1. Total issuance value | VND 75,478,630,000. |
| 1. Par value | VND 10,000/share. |
| 1. Issuance purposes | Increase the Company’s charter capital via the share issuance to increase share capital from the source of owners’ equity. |
| 1. Capital source for the issuance | Investment and development fund and undistributed profit after tax as of December 31, 2023 on the Audited Financial Statements 2023 of Hai Duong Pharmaceutical Medical Materials Joint Stock Company.  In which:   * Investment and development fund: VND 50,000,000,000. * Undistributed profit after tax: VND 25,478,630,000 (maximum). |
| 1. Eligible buyers | Existing shareholders according to the list of shareholders at the record date are entitled to receive shares issued from the source of owners’ equity announced by VSDC. |
| 1. Exercise rate | 100:37 (Shareholders owning 100 shares will receive 37 additional issued shares). |
| 1. Plan on handling fractional shares (if any) | The number of shares that each shareholder will receive in the share issuance to increase share capital from the source of owners’ equity owners will be rounded to the unit according to the principle of rounding; the number of fractional shares (decimal part) (if any) will be canceled and will not be issued.  For example: Shareholder Nguyen Van A owns 179 shares, shareholder A will receive additional issued shares calculated as follows: 179: 100) X 37 = 66.23 shares. Shareholder Nguyen Van A receives 66 new shares (0.23 fractional shares will be canceled). |
| 1. Expected execution time | Q2/2024, Q3/2024, after being approved by the General Meeting of Shareholders and notified in writing by the State Securities Commission of receiving full issuance report documents of DHD. |

‎‎Article 7. Approve the amendments and supplements to the Company's Charter of organization and operations according to Proposal No. 07/Ttr-HDQT of the Board of Directors.

‎‎Article 8. Approve the election of members of the Board of Directors for the term of 2024 - 2029 according to Proposal No. 08/Ttr-HDQT of the Board of Directors.

‎‎Article 9. Approve the election of members of the Supervisory Board for the term of 2024 - 2029 according to Proposal No. 09/Ttr- HDQT of the Board of Directors.

‎‎Article 10. Approve the election results of members of the Board of Directors for the term of 2024 - 2029.

The Meeting elected the following members to the Board of Directors of the Company for the term of 2024 - 2029:

1. Mr. Nguyen Trung Viet
2. Ms. Nguyen Thi Tu Anh
3. Mr. Tran Phuc Duong

‎‎Article 11. Approve the election results of members of the Supervisory Board for the term of 2024 -2024

The Meeting elected the following members to the Supervisory Board for the term of 2024 - 2029:

1. Ms. Pham Thi Thuy
2. Ms. Nguyen Thi Huong Lan
3. Mr. Tran Kim Cuong

The General Mandate was fully approved by the Annual General Meeting of Shareholders 2024 of Hai Duong Pharmaceutical Medical Materials Joint Stock Company right at the meeting. The Board of Directors, the Supervisory Board, the Board of Managers and related departments are responsible for implementing this General Mandate.

This General Mandate takes effect from the date of signing.